Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$973.47 USD

973.47
80,998

+5.49 (0.57%)

Updated May 17, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

4 FDA Decisions to Watch Out for in Apr 2017

by Arpita Dutt

Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

    Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

    by Zacks Equity Research

    Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

      Arpita Dutt headshot

      Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

      by Arpita Dutt

      Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

        Arpita Dutt headshot

        Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

        by Arpita Dutt

        Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

          Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

          by Zacks Equity Research

          Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

            What are Sanofi's (SNY) Strengths and Challenges in 2017?

            by Zacks Equity Research

            We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

              Arpita Dutt headshot

              Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

              by Arpita Dutt

              The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                Amgen's Repatha Meets Primary Endpoint in Phase III Study

                by Zacks Equity Research

                Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

                  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

                  by Zacks Equity Research

                  Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

                    Sweta Killa headshot

                    A Trip to 8-Year Bull Run: What's Up, What's Down

                    by Sweta Killa

                    While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.

                      Arpita Dutt headshot

                      5 FDA Decisions to Watch Out for in Mar 2017

                      by Arpita Dutt

                      Companies like Merck (MRK) are awaiting key FDA decisions this month.

                        Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss

                        by Zacks Equity Research

                        Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.

                          Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.

                            Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

                            by Zacks Equity Research

                            The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

                              Amgen Looking to Broaden Leukemia Drug Blincyto's Label

                              by Zacks Equity Research

                              Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                by Arpita Dutt

                                Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

                                  by Zacks Equity Research

                                  Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

                                    Ekta Bagri headshot

                                    Regeneron (REGN) Q4 Earnings Misses Estimates

                                    by Ekta Bagri

                                    Regeneron???s fourth-quarter 2016 earnings missed expectations

                                      Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

                                      by Zacks Equity Research

                                      Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

                                        Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?

                                        by Zacks Equity Research

                                        Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                                          by Arpita Dutt

                                          Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                                            Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                                            by Zacks Equity Research

                                            Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data

                                              by Arpita Dutt

                                              Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.

                                                SanofiRegeneron Sarilumab Approved in Canada for Arthritis

                                                by Zacks Equity Research

                                                Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

                                                  by Arpita Dutt

                                                  There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.